NIH ACTIV THERAPEUTICS MASTER PROTOCOL DESCRIPTIONS [……. at] ACTIV 6 you find: Trial launch on July 1, 2021 • Agent(s) being tested: IVERMECTIN, fluvoxamine, fluticasone
And if you follow the documentation you find: Status Summary of ACTIV Agents: […… at] ACTIV-6 you find: Continuing Enrollment (i.e., passed interim futility assessment): IVERMECTINE